STOCK TITAN
  1. Home
  2. News
  3. PROF

Profound Medical Corp - PROF STOCK NEWS

Welcome to our dedicated news page for Profound Medical (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Profound Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Profound Medical's position in the market.

News
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
Rhea-AI Summary
Profound Medical Corp. will release its first quarter 2024 financial results on May 9, followed by a conference call to discuss the results and business developments. The company specializes in customizable, incision-free therapies for diseased tissue ablation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Rhea-AI Summary
Profound Medical Corp. to provide business update at 2024 Bloom Burton & Co. Healthcare Investor Conference. The Company specializes in incision-free therapies for tissue ablation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
conferences
-
News
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Profound Medical Corp. reports strong financial results for Q4-2023 with a 60% revenue increase over the previous year. The company continues to grow its TULSA-PRO® systems installation base and collaborate with Siemens Healthineers. Profound also announces the promotion of Mathieu Burtnyk to COO and ongoing progress in the CAPTAIN trial. Despite revenue growth, operating expenses have increased, leading to a net loss for both the quarter and the full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.86%
Tags
earnings
News
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
Rhea-AI Summary
Profound Medical Corp. will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 13, 2024. The company develops incision-free therapies for tissue ablation and will broadcast the chat live on its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
conferences
-
News
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
Rhea-AI Summary
Profound Medical Corp. partners with Siemens Healthineers to offer a complete therapeutics solution combining TULSA-PRO® system with MAGNETOM Free.Max MRI scanner. The collaboration aims to provide innovative prostate cancer treatment with real-time MR guidance for precision. TULSA-PRO® allows for ablation of prostate tissue in a 'one-and-done' procedure, enhancing patient experience and recovery. The partnership is set to revolutionize prostate cancer diagnosis and treatment, improving outcomes for patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
News
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
Rhea-AI Summary
Profound Medical Corp. will announce its Q4 and full year 2023 financial results on March 7, 2024, with a conference call to discuss business developments. The Company develops incision-free therapies for tissue ablation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
earnings
News
Profound Medical Announces Non-Brokered Private Placement
Rhea-AI Summary
Profound Medical Corp. (PROF) has entered into subscription agreements with Canadian institutional investors for a non-brokered private placement, raising approximately US$2,937,502. The Company will issue 391,667 common shares at a price of US$7.50 per share, with the proceeds intended for commercialization and development of its medical systems and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
News
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues
Rhea-AI Summary
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced preliminary unaudited revenues for the fourth quarter and full year 2023, with total revenues for Q4 expected to be in the range of $1.9 million to $2.0 million, representing recurring revenue growth of 51% to 59% year-over-year. Full year 2023 revenues are anticipated to be in the range of $7.1 million to $7.2 million. The company is making progress with the commercialization of TULSA-PRO® in the United States and is focused on increasing the installed base and system utilization of TULSA-PRO® in preparation for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
-
News
Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares
Rhea-AI Summary
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) announced the pricing of its underwritten public offering of 2,666,667 common shares at a price to the public of US$7.50 per Common Share, led by healthcare focused institutional investors. Gross proceeds to the Company from the Offering are expected to be approximately US$20,000,000. Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the Offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
offering
News
Profound Medical Announces Proposed Public Offering of Common Shares
Rhea-AI Summary
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) announces the commencement of an underwritten public offering in the United States of common shares. The Company intends to file a preliminary prospectus supplement to its short form base shelf prospectus in the United States and Canada. The Offering will be priced in the context of the market, with the total size to be determined at the time of entering into an underwriting agreement. The Company expects to grant the underwriter an over-allotment option to purchase up to an additional 15% of the Common Shares. The net proceeds of the Offering are expected to be used to fund the continued commercialization of the TULSA-PRO® system in the United States, fund the continued development and commercialization of the TULSA-PRO® system and the Sonalleve® system globally, and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
offering
Stock PROF logo
Profound Medical Corp

Nasdaq:PROF

PROF Rankings

#3770 Ranked by Market Cap
#141 Ranked by Stock Gains
N/A Ranked by Dividends

PROF Stock Data

196.45M
22.21M
8.71%
41.01%
1.32%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Canada
Mississauga

About PROF

an inside out approach to prostate ablation profound medical is a canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients. profound’s novel technology combines real-time mr imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. it provides a highly precise treatment tailored to patient-specific anatomy and pathology. this method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. the potential of this technology is currently being demonstrated in clinical trials. for more information, visit profoundmedical.com